Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (6003)
All Articles published online
|
Publishing Process of This Article
|
Jan 27, 2020 (publication date) through Apr 24, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Hepatology
ISSN
1948-5182
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Chautant F, Guillaume M, Robic MA, Cadranel JF, Peron JM, Lison H, Cool C, Bureau C, Duhalde V. Lessons from “real life experience” of rifaximin use in the management of recurrent hepatic encephalopathy. World J Hepatol 2020; 12(1): 10-20 [PMID: 31984117 DOI: 10.4254/wjh.v12.i1.10] |
|---|---|
| URL: | https://www.wjgnet.com/1948-5182/full/v12/i1/10.htm |
| Number | Citing Articles |
| 1 |
Yasunari Hiramine, Hirofumi Uto, Seiichi Mawatari, Shuji Kanmura, Yasushi Imamura, Takuya Hiwaki, Akiko Saishoji, Atsuko Kakihara, Shigeho Maenohara, Koichi Tokushige, Akio Ido. Efficacy of rifaximin, a poorly absorbed rifamycin antimicrobial agent, for hepatic encephalopathy in Japanese patients. Hepatology Research 2021; 51(4): 445 doi: 10.1111/hepr.13622
|
| 2 |
Robert S. Rahimi, Kimberly A. Brown, Steven L. Flamm, Robert S. Brown. Overt Hepatic Encephalopathy: Current Pharmacologic Treatments and Improving Clinical Outcomes. The American Journal of Medicine 2021; 134(11): 1330 doi: 10.1016/j.amjmed.2021.06.007
|